ATE413170T1 - Medizinische zusammensetzung zur behandlung von infektionen mit arzneimittelresistentem staphylococcus aureus - Google Patents

Medizinische zusammensetzung zur behandlung von infektionen mit arzneimittelresistentem staphylococcus aureus

Info

Publication number
ATE413170T1
ATE413170T1 AT04705942T AT04705942T ATE413170T1 AT E413170 T1 ATE413170 T1 AT E413170T1 AT 04705942 T AT04705942 T AT 04705942T AT 04705942 T AT04705942 T AT 04705942T AT E413170 T1 ATE413170 T1 AT E413170T1
Authority
AT
Austria
Prior art keywords
staphylococcus aureus
resistant staphylococcus
medical composition
tara
beta
Prior art date
Application number
AT04705942T
Other languages
English (en)
Inventor
Tomihiko Higuchi
Hirofumi Shibata
Yoichi Sato
Nobuhisa Takaishi
Kazuyoshi Kawazoe
Kotaro Murakami
Original Assignee
Microbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbiotech Inc filed Critical Microbiotech Inc
Application granted granted Critical
Publication of ATE413170T1 publication Critical patent/ATE413170T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04705942T 2003-01-29 2004-01-28 Medizinische zusammensetzung zur behandlung von infektionen mit arzneimittelresistentem staphylococcus aureus ATE413170T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003020611 2003-01-29

Publications (1)

Publication Number Publication Date
ATE413170T1 true ATE413170T1 (de) 2008-11-15

Family

ID=32820629

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04705942T ATE413170T1 (de) 2003-01-29 2004-01-28 Medizinische zusammensetzung zur behandlung von infektionen mit arzneimittelresistentem staphylococcus aureus

Country Status (7)

Country Link
US (1) US20060235076A1 (de)
EP (1) EP1604660B1 (de)
JP (1) JP4693049B2 (de)
AT (1) ATE413170T1 (de)
DE (1) DE602004017586D1 (de)
ES (1) ES2316957T3 (de)
WO (1) WO2004066992A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007080669A1 (ja) * 2006-01-11 2007-07-19 Microbiotech Inc. 抗ウイルス・抗炎症作用薬剤組成物
WO2008065527A2 (en) * 2006-11-27 2008-06-05 Carlo Ghisalberti Gallic acid esters of fragrant alcohols
WO2008080162A2 (en) * 2006-12-22 2008-07-03 The Johns Hopkins University Anti-cholesterolemic compounds and methods of use
US20100056627A1 (en) * 2006-12-28 2010-03-04 Tomihiko Higuchi Pharmaceutical compositions of alkyl gallates
US8751346B2 (en) * 2011-05-13 2014-06-10 Edea, Llc. Interactive financial tool
US11690810B2 (en) * 2018-11-14 2023-07-04 The Chinese University Of Hong Kong Combination treatment of bacterial infection
KR102217338B1 (ko) * 2019-04-12 2021-02-18 주식회사 다인소재 섬기린초 유래 성분 및 베타 락탐계 항생제를 유효성분으로 함유하는 메티실린 내성 황색포도상구균에 대한 항균용 조성물
CN116650464A (zh) * 2023-05-30 2023-08-29 兰州理工大学 三没食子酸在制备β-内酰胺酶抑制剂中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3005012B2 (ja) * 1990-02-23 2000-01-31 三井農林株式会社 抗生物質耐性ブドウ球菌感染予防剤
JP2915802B2 (ja) * 1994-07-14 1999-07-05 呉羽化学工業株式会社 抗生物質耐性微生物の薬剤感受性増感剤
JPH09132532A (ja) * 1995-09-06 1997-05-20 Mitsui Norin Kk 抗生物質の抗菌力増強方法
JPH09194358A (ja) * 1996-01-23 1997-07-29 Alps Yakuhin Kogyo Kk 多価フェノール誘導体含有抗ｍｒｓａ活性医薬組成物
JPH1045528A (ja) * 1996-05-27 1998-02-17 Shiseido Co Ltd 抗酸化剤
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
JP4542644B2 (ja) * 1999-09-03 2010-09-15 株式会社林原生物化学研究所 抗菌作用の増強方法
WO2001030299A2 (en) * 1999-10-27 2001-05-03 Kemin Industries, Inc. Method of synthesizing alkyl gallates

Also Published As

Publication number Publication date
ES2316957T3 (es) 2009-04-16
US20060235076A1 (en) 2006-10-19
WO2004066992A1 (ja) 2004-08-12
DE602004017586D1 (de) 2008-12-18
JP4693049B2 (ja) 2011-06-01
EP1604660B1 (de) 2008-11-05
EP1604660A4 (de) 2007-03-21
JPWO2004066992A1 (ja) 2006-06-15
EP1604660A1 (de) 2005-12-14

Similar Documents

Publication Publication Date Title
CN102319246B (zh) 包含抗菌药以及一种选自麝香草酚、香芹酚的活性物质的药物组合物
HN2000000115A (es) Formulacion de sal comun y moxifloxacina
DE69433901D1 (de) Verbindungen und pharmazeutische zusammensetzungen zur behandlung und prophylaxe bakterieller infektionen
DE69934010D1 (de) Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
MX2021014554A (es) Antibioticos macrociclicos de amplio espectro.
DE69914911D1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
ATE413170T1 (de) Medizinische zusammensetzung zur behandlung von infektionen mit arzneimittelresistentem staphylococcus aureus
BR0309757A (pt) 6-alquilideno-penemas bicìclicos como inibidores de beta-lactamases
BRPI0411534A (pt) derivados de lincomicina com atividade antimicrobiana
CA3242451A1 (en) An injectable pharmaceutical composition for the treatment of respiratory diseases in animals
EP1639971A4 (de) Zusammensetzungen zum schutz der haut
CA2386685A1 (en) Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
JP5276653B2 (ja) カルバペネム類を含む殺菌性抗ｍｒｓａ活性医薬組成物
HRP20090022T3 (hr) Farmaceutski pripravci koji sadrže askorbinsku kiselinu za liječenje gljivičnih superinfekcija i gljivičnih recidiva
ATE417052T1 (de) Oxazaborolidine als bakterielle effektoren
NO20080314L (no) Bicykliske 6-alkyliden-penem B-laktamase inhibitorer og B-laktam antibiotisk kombinasjon: et bred spektret antibiotika
Das et al. Biofilm formation by pathogenic bacteria: the role of quorum sensing and physical-chemical interactions
WO2004041244A3 (en) Oral extended release tablets and methods of making and using the same
DE60237821D1 (de) Antibakterielle behandlung von osteoarthritis
DK1196439T3 (da) Forbindelser udvisende en antibiotikaaktivitet
AU2002360218A1 (en) A METHOD OF TREATING BACTERIAL INFECTIONS USING GEMIFLOXACIN OR A SALT THEREOF AND A Beta -LACTAM ANTIBIOTIC
WO2009077485A3 (en) 1(2)h-tetrazol-5-yl-phenyl-oxazolidinones as antibacterial agents
BR9712633A (pt) Método para o tratamento de infecção por streptococcus pneumoniae

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties